Valuation
- Market cap
- 15,729,000
- Revenue TTM
- $2,070,000
- Net income TTM
- $-3,530,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -170.53%
- Debt to equity
- 0.00
Trading
- Volume
- 437,400
- Avg volume
- 50,232
- Day's range
- $2.82 – $3.84
- Shares out
- 4,681,000
- Stochastic %K
- 23%
- Beta
- 1.75
- Analysts
- —
- Price target
- $8.00
Company profile
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Pralicig...
Show more
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 327 8778
- Website
- https://www.cyclerion.com
- Address
- 245 First Street, Riverview II, 18th Floor, Cambridge, United States
Latest news
No headlines yet.
